{
    "clinical_study": {
        "@rank": "134395", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: BIND-014 every 3 weeks", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B: BIND-014 weekly", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients\n      with advanced non-small cell lung cancer (NSCLC)."
        }, 
        "brief_title": "A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females at least 18 years of age\n\n          -  Diagnosis of NSCLC with locally advanced or metastatic disease\n\n          -  Previously treated with one platinum-based chemotherapy\n\n          -  Disease status must be that of measurable and/or evaluable disease\n\n          -  Performance status of 0 to 1 on the ECOG Scale\n\n          -  Prior chemotherapy completed at least 3 weeks prior to study enrollment\n\n          -  Prior radiation therapy allowed to < 25% of the bone marrow\n\n          -  Patient compliance and geographic proximity that allow adequate follow-up\n\n          -  Adequate organ function\n\n          -  Patients with reproductive potential must use contraceptive methods\n\n          -  Signed informed consent from patient\n\n        Exclusion Criteria:\n\n          -  Active infection\n\n          -  Pregnancy or planning to become pregnant\n\n          -  Breast feeding\n\n          -  Serious concomitant systemic disorders\n\n          -  Second primary malignancy\n\n          -  Patients who are symptomatic from brain metastasis\n\n          -  Presence of detectable (by physical exam) third-space fluid collections\n\n          -  More than 1 prior cytotoxic chemotherapy regimen for advanced disease\n\n          -  Prior treatment with docetaxel\n\n          -  History of severe hypersensitivity reaction to polysorbate 80\n\n          -  Peripheral neuropathy at study entry\n\n          -  Patients known to be HIV positive\n\n          -  Patients known to be seropositive for hepatitis C hepatitis B\n\n          -  Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792479", 
            "org_study_id": "BIND-014-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A: BIND-014 every 3 weeks", 
                "Arm B: BIND-014 weekly"
            ], 
            "intervention_name": "BIND-014", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NSCLC", 
            "lung cancer"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Goodyear", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85338"
                    }, 
                    "name": "Investigative Site #10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Investigative Site #04"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Meyers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33905"
                    }, 
                    "name": "Investigative Site #02"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newnan", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30265"
                    }, 
                    "name": "Investigative Site #08"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zion", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60099"
                    }, 
                    "name": "Investigative Site #07"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Investigative Site #03"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "74133"
                    }, 
                    "name": "Investigative Site #09"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19124"
                    }, 
                    "name": "Investigative Site #11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "Investigative Site #05"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Investigative Site #01"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "454087"
                    }, 
                    "name": "Investigative Site #15"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115478"
                    }, 
                    "name": "Investigative Site #12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersberg", 
                        "country": "Russian Federation", 
                        "zip": "198255"
                    }, 
                    "name": "Investigative Site #14"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersberg", 
                        "country": "Russian Federation", 
                        "zip": "97758"
                    }, 
                    "name": "Investigative Site #13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ufa", 
                        "country": "Russian Federation", 
                        "zip": "450054"
                    }, 
                    "name": "Investigative Site #16"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "jsumma@bindtherapeutics.com", 
            "last_name": "Jason Summa"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the efficacy of BIND-014 as measured by objective response rate (ORR) in patients with Stage III/IV Non-small cell lung cancer (NSCLC) who have failed one prior platinum containing chemotherapy regimen for advanced or metastatic disease.", 
            "measure": "Number of patients with either a complete or partial response", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of treatment, an expected average of 18 weeks"
        }, 
        "reference": {
            "PMID": "22491949", 
            "citation": "Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 4;4(128):128ra39. doi: 10.1126/scitranslmed.3003651."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the safety and tolerability of BIND-014", 
            "measure": "Number of patients who experience adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be followed for the duration of treatment, an expected average of 18 weeks"
        }, 
        "source": "BIND Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BIND Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}